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Glutamate-system defects behind 
psychiatric manifestations in a 
familial hemiplegic migraine type 2 
disease-mutation mouse model
Pernille Bøttger1,2,3, Simon Glerup1,4, Bodil Gesslein5, Nina B. Illarionova6, Toke J. Isaksen1,2, 
Anders Heuck1,2, Bettina H. Clausen3, Ernst-Martin Füchtbauer7, Jan B. Gramsbergen3, 
Eli Gunnarson6, Anita Aperia6, Martin Lauritzen5,8, Kate L. Lambertsen3, Poul Nissen2,7,9 & 
Karin Lykke-Hartmann1,2,10
Migraine is a complex brain disorder, and understanding the complexity of this prevalent disease 
could improve quality of life for millions of people. Familial Hemiplegic Migraine type 2 (FHM2) is a 
subtype of migraine with aura and co-morbidities like epilepsy/seizures, cognitive impairments and 
psychiatric manifestations, such as obsessive-compulsive disorder (OCD). FHM2 disease-mutations 
locate to the ATP1A2 gene encoding the astrocyte-located α2-isoform of the sodium-potassium 
pump (α2Na+/K+-ATPase). We show that knock-in mice heterozygous for the FHM2-associated 
G301R-mutation (α2+/G301R) phenocopy several FHM2-relevant disease traits e.g., by mimicking 
mood depression and OCD. In vitro studies showed impaired glutamate uptake in hippocampal 
mixed astrocyte-neuron cultures from α2G301R/G301R E17 embryonic mice, and moreover, induction of 
cortical spreading depression (CSD) resulted in reduced recovery in α2+/G301R male mice. Moreover, 
NMDA-type glutamate receptor antagonists or progestin-only treatment reverted specific α2+/G301R 
behavioral phenotypes. Our findings demonstrate that studies of an in vivo relevant FHM2 disease 
knock-in mouse model provide a link between the female sex hormone cycle and the glutamate 
system and a link to co-morbid psychiatric manifestations of FHM2.
Familial Hemiplegic Migraine type 2 (FHM2) is a chronic and hereditary disorder with severe episodic attacks of 
migraine with aura (MA) fulfilling the classic migraine criteria1. FHM2 is a rare form of migraine with aura that 
involves motor aura (weakness) and frequently accompanied by co-morbid epilepsy/seizures2,3, and in a subset 
of FHM2-families cognitive impairments and/or different psychiatric manifestations such as mood depression, 
anxiety and obsessive compulsive disorder (OCD) have been reported2,4 as well as co-occurrence of obesity and 
other migraine forms5,2.
In the majority of FHM2-families, the disease is caused by haploinsufficiency due to loss-of-function muta-
tions in the ATP1A2-gene, which encodes the α 2-isoform of the Na+/K+-ATPase (a sodium pump)2,6. The sodium 
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pump directs ion gradients (3Na+out/2K+in) which, in conjugation with other pump-independent functions, are 
implicated in various basic and specialized cellular functions. In the adult brain, the α 2Na+/K+-ATPase is pre-
dominantly expressed in astrocytes7, and the astrocytic glutamate transporters of the EAAT family (excitatory 
amino acid transporters) uses the steep Na+-gradient maintained by the sodium pump as driving force for glu-
tamate clearance from the synaptic cleft8–10. Moreover, the α 2Na+/K+-ATPase do also co-localized with EAAT1 
(GLAST) and EAAT2 (GLT-1)) in the astrocytic plasma membrane11,12.
Ovarian hormones significantly influence migraine13, and women have a higher prevalence of migraine after 
puberty, with a lifetime prevalence of 25% compared with 8% in men. A link between the female sex hormone 
cycle and the glutamate system was recently demonstrated since the selective estrogen receptor modulator 
(SERM) raloxifene was shown to upregulate EAAT2 and EAAT1 expression in rat primary astrocytes14.
One of the characteristic symptoms of FHM2 is the aura phenomenon appearing before the onset of the 
hemiplegic migraine. It is widely accepted that cortical spreading depression (CSD) is the molecular mechanism 
behind aura15. CSD gives rise to a propagating wave of neuronal and glial depolarization, which is accompanied 
by a massive distribution of ions between the extracellular space and intracellular department16. Two FHM1 
knock-in mouse models17,18 and an Atp1a2 mouse model harboring the W887R mutation19 revealed increased 
susceptibility to CSD compared to WT mice supporting CSD as a trigger to migraine. In this regard, it is notewor-
thy that while most of the ATP1A2 mutations (and also the W887R mutation) are associated with pure FHM2, the 
ATP1A2 G301R mutation represents a particular severe phenotype with an early onset.
In this study, we have generated an α 2Na+/K+-ATPase knock-in (KI) mouse model (α 2+/G301R) by introduction 
of the FHM2-associated G301R mutation described in two FHM2-families4,20. The α 2+/G301R mice displayed sev-
eral behavioral phenotypes mimicking compulsive behavior and OCD, decreased sociability and stress-induced 
depression-like phenotypes. Interestingly, the α 2+/G301R mice displayed female-specific behaviors in several tests, 
and those behaviors—and the compulsive behaviors—were rescued by drug treatments targeting the female sex 
hormone cycle or the glutamate system. Altogether our results link the female sex hormone cycle and the gluta-
mate system and a link to co-morbid psychiatric manifestations of FHM2.
Materials and Methods
Generation of the α2+/G301R mouse line. Cloning of the targeting construct for generating α2+/G301R mice. 
On the basis of 129/SvJ Atp1a2-gene fragments covering intron 6 to intron 13, the final targeting construct (total 
16 691 bp) was generated using the pSC-B cloning vector as backbone (3.5 kb, Stratagene Corp, La Jolla, CA, 
USA). The targeting construct contained unmodified Atp1a2-gene stretches of 2.1 kb and 4.4 kb for cross-over 
(= recombination arms), a 2 × herpes simplex thymidine kinase (2 × TK) cassette (in SacII site in multiple clon-
ing site) conferring sensitivity to 1-(2′ -deoxy-2′ fluoro-1-ß-D-arabinofuranosyl)-5-iodouracil (FIAU), a floxed 
neomycin (NEO) gene cassette (in AflII site in intron 7) conferring resistance to G418, and a modified Atp1a2 
genomic DNA stretch, which harbored a third LoxP site (abolishing a BstEII site in intron 8) in addition to the 
G→ A mutation in exon 8 (G→ A in position 901 post start codon in mRNA, NCBI accession NM_178405, mouse 
strain C57BL/6) that introduced the G301R mutation. A detailed cloning strategy is listed in Supplementary Table 
1. Note that the second of two LoxP sites in the targeting constructs was introduced for the possibility of generat-
ing conditional α 2+/KO mice (by crossing to Cre-expressing mice).
Gene targeting by homologous recombination. Murine 129S1/Sv-derived CJ7 embryonic cells21 were electro-
porated with PvuI-linearized targeting construct, and G418-resistant (350 μ g/mL) and FIAU-sensitive (0.5 μ M) 
colonies were selected and expanded (DAGMAR facility, Aarhus University, Aarhus, Denmark (http://dagmar.
au.dk)). Homolog recombination in ES cell clone IIH6 was confirmed by 5′end and 3′ end PCR’s using primers 
located to the NEO cassette sequence and primers located to Atp1a2 sequences flanking the Atp1a2 sequences 
covered by the targeting construct, and a NEO PCR using the two NEO primers together (Supplementary Table 1). 
Moreover, homolog recombination in ES cell clone IIH6 was confirmed by Southern blotting with a probe bind-
ing to Atp1a2 sequence flanking the Atp1a2 sequence in the 5′ end of the targeting construct (Supplementary 
Table 1) (DAGMAR facility). The NEO cassette was removed by partial Cre-enzyme treatment leaving a sin-
gle LoxP site in intron 7 obtained by transfecting IIH6 ES cells with linearized Cre-enzyme encoding plasmid 
(DAGMAR facility). Successful partial Cre-enzyme treatment was confirmed for the IIH6Cre14 clone by PCR 
and digestions of the PCR product generated specific band patterns (Supplementary Table 1).
Generation and breeding of the transgenic α2+/G301R knock-in (KI) mice. ES cells (IIH6cre14 clone) were indi-
vidually injected into C57BL/6J blastocysts, which were then introduced into pseudo-pregnant female mice that 
gave birth to chimeric mice (DAGMAR facility). Two male chimeric mice were mated with C57BL/6J^BomTac^ 
(denoted C57BL/6J in this paper) female mice (Taconic Farms Inc, Bomholt, Denmark), and germ line trans-
mission was obtained. Heterozygous α 2+/G301R mice were identified by PCR genotyping (Supplementary Table 
1; protocol will be provided upon request) and subsequent BstEII digestion, which generated a specific band 
pattern; note, that all mice were also retro-genotyped. In initial crossings between heterozygous α 2+/G301R male 
and female mice, homozygous α 2G301R/G301R pups were born, however they died neonatally in agreement with 
other mouse models targeting the Atp1a2-gene19,22–24. From four independent crossings, the α 2G301R/G301R mice, 
α 2+/G301R mice, and (α 2+/+) littermates (WT) were born at the ratio 1:1:1 (9 α 2G301R/G301R, 10 α 2+/G301R, 10 WT) and 
generated fewer α 2+/G301R mice than expected according to Mendel’s law of segregation. All in vivo studies were 
performed using α 2+/G301R mice and WT obtained by crossing α 2+/G301R mice (generation N ≥ 8) with C57BL/6J 
mice (Taconic Farms Inc). Ten independent, and randomly chosen, breedings of α 2+/G301R mice with C57BL/6J 
mice that generated 80 offspring were assessed; the offspring distributed at the ratio 1:1 regarding sex (38 females, 
42 males) and at the ratio 1:1 regarding genotype (43 α 2+/G301R (23 females, 20 males), 37 WT (15 females, 22 
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males), and showed that breeding generated offspring with a normal distribution of females and males and the 
expected distribution of genotypes (where genotypes were distributed at the ratio 1:1 regarding sex) according 
to Mendel’s law of segregation. The α 2+/G301R mice appeared grossly normal and were indistinguishable from 
WT mice by eye. Mice were housed in a room under a 12:12 light/dark cycle (lights on between 6:30A.M. and 
6:30P.M.) in cages with littermates of same sex. Food and water were provided ad libitum. Experimental protocols 
involving mice, performed at Aarhus University and Copenhagen University, were done according to the Danish 
national and institutional regulations and approved by the Animal Experiments Inspectorate under the Danish 
Ministry of Justice (permit numbers 2012-15-2934-00621, 2013− 15− 2934− 00815 and 2012-15-2934-00063). 
Moreover, experimental protocols involving mice, performed at Karolinska University, were done according to 
the European Communities Council Directive of 24 Nov. 1986 (86/609/EEC) and approved by the Northern 
Stockholm Laboratory Animal Review Board (permit number N132/12).
All behavioral experiments were done blind to genotype with age-matched littermates.
Body weight development. Each mouse was weighed every week from day 0 to day 190, and in intervals hereafter 
up to 360 days. The body weight (g) was determined with two decimals (FX-3000i, A&D Company Ltd, Tokyo, 
Japan). The data, given as body weights (g) at the given days, was shown as means and analyzed using two-way 
ANOVA, see Supplementary Table 1.
SDS-page Western blotting. Crossing of two heterozygous α 2+/G301R mice generated newborn pups of all 
genotypes (homozygotes (− /− ), heterozygotes (+ /− ) and WT (+ /+ )) which were decapitated, and to each 
brain, 0.3 mL ice-cold lysis-buffer (1% sodium dodecyl sulfate (SDS), 1 mM Na3VO4, protease inhibitor cocktail 
(CompleteTM (mini, EDTA-free), 04 693 159 001, Roche Diagnostics GmbH, Mannheim, Germany), 10 mM Tris 
(pH 7.4)) was added, and next grinded 10 × using a 60 μ m pestle in a glass rod (885301-0002 tissue grinder, 
Kimble Chase, Gerresheimer Glass Inc, Vineland, NJ, USA). The lysates were centrifuged 2 min, 1,000 × g at 
4 °C, and the supernatants were aliquoted and samples were stored at − 80 °C. Two adult male and female mice 
of each genotype were decapitated. The brains from two mice were dissected into hippocampus (HC), cortex 
(CTX), brain stem (BS) and cerebellum (CRBL) and the brain areas were stored on ice. Immediately hereafter, 
the brain areas from two mice were pooled and 0.4 mL (HC) or 0.8 mL (other) ice-cold lysis-buffer was added, 
and hereafter handling was as described above. Male and female α 2+/G301R mice were mated, and vaginal plug 
was noted. Pregnant female mice were sacrificed 17 days after conception, and the embryos (E17.5) were dis-
sected, measured, and the embryonic stage was confirmed by the length (in cm) and their visual appearance. The 
embryos were decapitated and the whole brains were collected and to each brain, 0.3 mL ice-cold lysis-buffer was 
added, and hereafter handling was as described above. The protein content in all samples was determined using 
a method adapted from Bradford25 (protein assay kit 1, 500-001, Bio-Rad Laboratories Inc, Berkeley, CA, USA). 
In total, 25 or 30 μ g of protein lysates in reducing sample-buffer (58 mM Tris (pH 6.8), 5% (v/v) glycerol, 1.7% 
(w/v) SDS, 0.002% (w/v) bromphenol blue, 100 mM dithiothreitol (DTT)) (no boiling) and a molecular weight 
standard marker (spectraTM multicolor broad range protein ladder (SM1841, Fermentas, Thermo Fisher Scientific 
Inc, Waltham, MA, USA)) were separated by SDS-page using 10% uniform polyacrylamide gels and blotted 
onto 0.45 μ m pore-sized polyvinylidene fluoride (PVDF) membranes (IPVH00010 ImmobilonR-P, Millipore 
Corp, Bedford, MA, USA). The blots were blocked for 1 hour at room temperature (RT) in blocking solution 
(5% swine serum in phosphate-buffered saline (PBS (pH 7.4)) with 0.05% detergent (Tween-20) (PBS-T)). 
The blots were incubated with primary antibody (polyclonal rabbit anti-human α 2 aa 432–455, 07674 Upstate, 
Millipore Corp, polyclonal rabbit anti-rat α 3, aa 320–514, 06172 Upstate, Millipore Corp, and monoclonal mouse 
anti-chicken α 1, polypeptide 1020 aa, developed by Douglas M. Fambrough, obtained from the Developmental 
Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The University of 
Iowa, Department of Biology, Iowa City, lA 52242) over-night at 4 °C, diluted 1:5000 (α 2 antibody) and 1:1000 
(α 1 and α 3 antibodies) in blocking solution, followed by 3 × 10 min wash-steps in PBS-T at RT. The blots were 
then incubated with secondary antibody (horseradish peroxidase (HRP)-conjugated polyclonal swine anti-rabbit 
IgG, P0217, Dako Inc, Glostrup, Denmark) for 1 hour at RT diluted 1:1 000 in 5% (w/v) nonfat dry milk in PBS-T, 
followed by 3 × 10 min wash-steps in PBS-T at RT. Note that blocking, incubations, and in-between washes were 
done on a rocking table. The blots were developed using a chemiluminescent substrate according to the manu-
facturer’s instructions (ECLTM western blotting analysis system, RPN2109, AmershamTM, GE Healthcare, Little 
Chalfont, Buckinghamshire, UK) and visualization occurred by use of a scientific imaging system (LAS-3000 
Luminescent Image Analyzer, Fuji film Corp, Kanagawa, Japan). After development, the blots were stripped at 
RT by incubating 15 min in H2O, 2 × 15 min in 0.1 M NaOH, 15 min in H2O, followed by 30 min in PBS-T. The 
blots were blocked for 1 hour at RT in blocking solution (5% swine serum in PBS-T). The blots were incubated 
with primary antibody (polyclonal rabbit anti-human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (aa 
1–335, sc-25778, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA) over-night at 4 °C diluted 1:200 in block-
ing solution, followed by 3 × 10 min wash-steps in PBS-T at RT. The blots were then incubated with secondary 
antibody and developed as described above.
The SDS-page Western blotting experiments were performed at least twice using independent samples, and 
representative blots were subjected to densitometric analysis where the intensity of the bands was quantified 
as arbitrary units, AU or Quantum Level, QL (note that background stain in each lane was also determined in 
parallel and subsequently subtracted). Densitometry was performed using the Multi Gauge v3.2 software (Fuji 
film Corp), see Supplementary Table 1. The level of α 2-protein relative to GAPDH in lysates made from WT 
E17.5 embryos and newborn pups was set to 100%. In the experiments where more than one WT lysate was 
tested, the specific level of α 2-protein relative to GAPDH was normalized to the average level of α 2-protein in 
WT lysates. The relative α 2-protein level in lysates from the different genotypes in % is shown as means ± s.e.m 
(Supplementary Table 2). For adult Western blot quantification, ImageJ was used to obtain a numerical value 
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corresponding to the intensity for each band of interest. The three α -isoform protein levels were measured relative 
to GAPDH for both genotypes and WT ratios were set to 100%. The relative α -isoform protein levels obtained for 
heterozygotes (+ /− ) are shown as means ± s.e.m. The specificity of the α 2 antibody was confirmed on a Western 
blot of rat brain microsomal preparation and allowed for recognition of a protein of 105 kDa (company product 
sheet), and specificity of the GAPDH antibody was confirmed on a Western blot of HeLa and JAR cell lysates and 
mouse placenta tissue and allowed for recognition of a protein of 37 kDa (company product sheet).
Electrophysiology. Surgery. Mice were anesthetized by intraperitoneal (i.p.) injections of a mixture of 
ketamine (60 mg/kg) and xylazine (10 mg/kg) (Sigma-Aldrich Co, St Louis, MO, USA), and they were given 
supplemental doses of ketamine every 20 min. Body temperature was maintained at 37 °C using a tempera-
ture controller and a heating blanket (model TC-1000 Temperature Controller, CWE Inc, Ardmore, PA, USA). 
The trachea was cannulated for mechanical ventilation with a small-animal ventilator (SAAR-830, CWE Inc). 
Catheters (100828 DiLab, VeruTech AB, Lund, Sweden) were placed into the left femoral artery and vein and 
perfused with physiological saline. The end-expiratory CO2 (microCapstar End-tidal CO2 Monitor, CWE) and 
blood pressure (Pressure Monitor BP-1, World Precision Instruments, Sarasota, FL) were monitored continu-
ously in combination with blood gases in arterial blood samples (pO2: 115–130 mmHg; pCO2: 35–40 mmHg; pH: 
7.35–7.45; ABL 700 Series; Radiometer Medical, Brønshøj, Denmark) to ensure that animals were kept under 
physiological conditions. Two craniotomies were performed with a dental drill; one (2-mm-diameter) placed 
over the barrel cortex was used for recording, and the other (1-mm-diameter) placed over the rostral parietal 
lobe was used for elicitation of cortical spreading depression (CSD). The dura was carefully removed and visible 
signs of brain damage or bleeding excluded mice from the experiment. During and after removal of the dura, the 
craniotomy sites were continuously superfused with artificial cerebrospinal fluid (aCSF) (aCSF composition in 
mM: 2.0 glucose, 126.0 NaCl, 2.8 KCl, 22.0 NaHCO3, 1.45 CaCl2, 1.0 Na2HPO4, and 0.876 MgCl2). The craniot-
omies were covered with a drop of 0.75% agarose in saline. After the preparation and application of electrodes 
and probes, anaesthesia was changed to α -chloralose (50 mg/kg/hour, intravenous (i.v.), Sigma-Aldrich Co) that 
is the best regime to study cerebral blood flow26,27. For schematic drawing of setup, see Fig. 1a. Experiments were 
performed after a postoperative recovery period of at least 30 min in order to obtain a stable level of anaesthesia, 
a stable laser-Doppler baseline, and an arterial blood pressure of 80–110 mmHg. In the end, mice were killed by 
an overdose of anaesthesia and decapitated afterwards.
Induction of cortical spreading depression. CSD was elicited in the right somatosensory cortex by pressure injec-
tion of potassium acetate (KAc, 1 M), and propagated to the barrel cortex. KAc has the advantage over KCl that 
the tissue is similarly depolarized by K+ while Ac serves as an anion substitution decreasing the Cl− concentration 
and hence the Cl− gradient across the plasma membrane. To allow for induction of single CSD, a micropipette 
was filled with KAc, connected to a picopump (World Precision Instruments) and inserted into the craniotomy 
at a depth of approximately 200 μ m. KAc was injected during 1–2 s with a 4–6 psi pressure. If no CSD was elicited 
within 3 min, the injection was repeated until a CSD was elicited. If no CSD was elicited after 3 trials, the injection 
electrode was retracted to verify that it had not been clogged, before injections continued. Spontaneous CSD 
events were observed in few mice (1:8 WT mice and 1:9 α 2+/G301R mice) after the first CSD event was induced. 
Notably, these rare spontaneous CSD events could be the result of e.g., remaining KAc in the tissue or KAc from 
a leaking electrode. The data, given as CSD propagation speed (for a single CSD event) (μ m/s), was shown as 
mean ± s.e.m. and analyzed using Student’s two-tailed, unpaired t-test, see Supplementary Table 3.
Electrophysiological recording. The electric signals of the CSD were monitored by two glass microelectrode 
recording both electrocorticographic (ECoG) signal and the direct current (DC). The DC was recorded to follow 
the voltage shift during the CSD. ECoG signal constitutes the total electrical signal (without the DC offset) from 
the cortex surrounding the electrode and is composed of spikes and spontaneous local field potentials, where the 
largest component is low (< 100 Hz) frequency signal. The glass microelectrodes used were single-barrelled, filled 
with 2 M saline. Two electrodes were placed at a depth of approximately 150 μ m in the right somatosensory cortex 
and they were separated to allow for measurement of the CSD propagation speed. The DC signals were amplified 
using a differential amplifier (gain × 10, bandwidth 0.1–5 000 Hz, DP-311, Warner Instruments, Hamden, CT, 
USA), A/D converted (20 kHz) and low pass filtered (5 kHz). The ECoG signal was obtained by amplification of 
the DC signal using CyberAmp 380 (gain × 100, bandwidth 0.1–5 000 Hz; Axon Instruments Inc, Foster City, CA, 
USA); these signals were digitized using the 1401 plus hardware connected to a computer running the Spike 2.7 
software (Cambridge Electronic Design). Stimulation of the mouse whisker pad was done to assess the evoked 
potentials. Mouse sensory barrel cortex was stimulated contralateral to the craniotomy, in the ramus infraorbita-
lis of the trigeminal nerve by a set of custom-made bipolar electrodes inserted percutaneously. The cathode was 
positioned corresponding to the hiatus infraorbitalis (IO) and the anode was inserted into the masticatory mus-
cles. The thalamocortical IO stimulation was done with an intensity of 1.5 mA (ISO-flex, A.M.P.I., Israel) lasting 
1 ms, in trains of 15 s at 0.5 Hz. The stimulation was controlled by a sequencer file running within the Spike2 soft-
ware (version 7.02, Cambridge Electronic Design) and recorded with the same glass microelectrode as for ECoG 
signal. The amplitude of the local field potentials were summed over the duration of the stimulation (summa LFP) 
and presented as % relative to pre-CSD induction as means ± s.e.m. and analyzed using a linear mixed model, see 
Supplementary Table 3. Evoked potentials were recorded before the CSD and 15 min after the CSD (stimulations 
were not performed at 0–15 min in order to not perturb the ECoG signal with repeated stimulations which poten-
tially could influence the rate of recovery of the ECoG signal).
The ECoG signal was root mean squared and averaged over periods of 1 min and presented as % of the total 
electrical signal relative to pre-CSD induction and as mV, were shown as means ± s.e.m. and analyzed using a 
linear mixed model, see Supplementary Table 3.
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Cerebral blood flow measurements. CBF was recorded continuously using a laser-Doppler flowmetry (LDF) 
probe at a fixed position 0.3 mm above the pial surface in a region devoid of large vessels (wavelength 780 nm; 
250 μ m fiber separation allowing CBF measurement to a depth of 1 mm; Perimed AB, Järfälla, Sweden)28. The 
probe was placed close to one of the microelectrodes recording electrophysiological variables. The LDF signal was 
smoothed with a time constant of 0.2 s (PeriFlux 4001 Master, Perimed AB), sampled at 10 Hz, analog-to-digital 
(A/D) converted, and digitally recorded and smoothed (time constant 1 s) using the Spike2 software (Cambridge 
Electronic Design). The LDF method does not measure CBF in absolute terms, but is valid in determining relative 
changes in CBF during moderate flow increases29.
The CBF baseline was evaluated as % of pre-CSD baseline with a 5 min average value was calculated before 
CSD and a 1 min average value was calculated 5, 10, 15, 20, 30, 40, 50 and 60 min after CSD. Data is shown as 
means ± s.e.m. and analyzed using a linear mixed model, see Supplementary Table 3.
Behavioral Analysis. Open field. Each individual mouse was placed in a bright grey, squared plastic box 
(45 × 45 × 45 cm), and the movement of the mouse was recorded using the SMART video tracking software 
system (version 2.5.20, Panlab Harvard Apparatus, Cornellà (Barcelona), Spain) connected to a video camera 
(SSC-DC378P, Sony Corp, Tokyo, Japan) placed directly above the box for 10 min30. The system automatically 
recorded the total distance travelled (m), mean velocity (cm/s) and time (s) spent in each zone (17.6 × 16.1 cm 
imaginary square). The number of groomings (n), urinations (n) and droppings (n) were counted manually. 
Each mouse was tested once, and the open field setup was cleaned with 70% ethanol and wiped with paper towels 
between each trial. The data, given as distance travelled (m), mean velocity (cm/s), faecal boli (n), urinations (n) 
and center/perimeter ratio, were shown as means ± s.e.m. and analyzed using Student’s two-tailed, unpaired t-test 
with Welch’s post hoc correction where indicated in Supplementary Table 4. Two-sided Fisher’s exact test was used 
where Student’s two-tailed, unpaired t-test was not applicable, see Supplementary Table 4.
Accelerating rotarod test. The rotating rod apparatus (Rota-rod/RS, PanLab Harvard Apparatus) was used to 
measure the ability of mice to improve motor skill performance/coordination with training. Mice were placed on 
the rod (3-cm-diameter) for three trials per day for four consecutive days. The first day consisted of 3 × training 
trials where no data were obtained. The next three days, the first trial of the day was a training trial where no 
data were obtained, whereas the following two trials were recorded using the SeDaCom software system (version 
1.4.02, PanLab Harvard Apparatus). When a mouse fell off the rotarod, it was reintroduced to the rotarod once 
more, and if the latency to fall this time was more than 20 s, then this latency (s) was added to the latency to fall 
(s) obtained first. Each trial lasted a maximum of 5 min, and during this time, the rotating rod underwent a lin-
ear acceleration from 4 to 40 rpm. Thus, mice were scored for their latency to fall (s) for two trials a day, and the 
average of these latencies was the latency to fall (s) for a given mouse on that given day. Mice rested a minimum 
of 20 min between trials to avoid fatigue and exhaustion. The rotarod was cleaned with 70% ethanol and wiped 
with paper towels between each trial. The data, given as latencies to fall (s) at the indicated days, were shown as 
means ± s.e.m. and analyzed using two-way ANOVA, see Supplementary Table 4.
Grip strength. The total grip strength was measured using a grip strength meter (Bio-GT3, Bioseb, Panlab 
Harvard Apparatus). The mouse was allowed to grasp the metal grid with both front paws and then pulled back-
wards in the horizontal plane. The force at the moment when the mouse lost its grip was recorded as the peak ten-
sion given in grams (g). Each mouse was tested in 5 sequential trials, and the highest grip strength was recorded 
as the grip strength parameter30. In parallel, the body weight (g) of each mouse was determined. The data, given 
as grip strength (g) relative to body weight (g), were shown as means ± s.e.m. and analyzed using Student’s 
two-tailed, unpaired t-test with Welch’s post hoc correction, see Supplementary Table 4.
Estradiol levels in serum. Blood (approximately 200–300 μ L) from individual mice was collected from the neck 
after decapitation and allowed to clot 30 min at RT. The samples were centrifuged at ~2 000 × g at 4 °C, 15 min. 
The serum was transferred to new tubes and the centrifugation step was repeated. Serum was aliquoted and 
stored at − 80 °C. The estradiol assay protocol (Mouse/Rat Estradiol ELISA ES180S-100, Calbiotech Inc, Spring 
Valley, CA, USA) was followed, and 2 × 25 μ L serum was analyzed for the estradiol level (pg/mL) according to the 
manufacturer’s instructions. The data, given as estradiol levels (pg/mL), were shown as means and analyzed using 
Student’s two-tailed, unpaired t-test, see Supplementary Table 5. Notably, our data were comparable to previous 
findings31.
High performance liquid chromatography (HPLC) and electrochemical detection of monoamines and GABA. After 
decapitation, the brain was quickly removed from the skull and different brain regions were rapidly dissected, 
placed on dry ice, weighed (mg), and stored at − 80 °C. At the day of HPLC analysis, the brain tissue samples 
were briefly sonicated in Eppendorf vials containing 200–800 μ L (about 1:20 w/v) of 0.1 M perchloric acid 
(PCA) with antioxidants (0.2 g/L Na2S2O5, 0.05 g/L Na2-EDTA) and centrifuged at 20 627 × g for 20 min at 
4 °C. The supernatant was used for HPLC analysis of monoamines and gamma-aminobutyric acid (GABA). 
The perchlorate extracts were immediately used for analysis of monoamines and stored at 4 °C for maximally 
2 weeks until analysis of GABA. Levels (pmoles/mg wet tissue) of noradrenalin (NA), dopamine (DA), seroto-
nin (5-hydroxytryptamine, 5-HT) were assessed by reverse-phase HPLC with electrochemical detection, essen-
tially as described previously32, but using a mobile phase consisting of 10% methanol (v/v), 20 g/L citric acid 
monohydrate, 100 mg/L octane-1-sulfonic acid sodium salt, 40 mg/L EDTA dissolved in Milli-Q water and pH 
adjusted to 4.0 according to the protocol (Santiago et al. 2010). The Merck-Hitachi HPLC system consisted of 
an L-7100 pump, an L-7200 autosampler, a D-7000 interface and an electrochemical detector with in-built col-
umn oven (Decade, Antec, Leiden, The Netherlands), connected to a computer equipped with D-7000 version 
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2.0 chromatography software. The mobile phase was pumped at a flow rate of 0.9 mL/min through a Waters 
Spherisorb S5 ODS2 guard column (4.6 × 30 mm, Waters Corp, Milford, MA, USA) and a Waters Spherisorb S3 
ODS2 cartridge analytical column (4.6 × 150 mm, Waters Corp). A mixture of external standards of monoamines 
and its metabolites (Sigma-Aldrich Co) was injected (0.5–1 pmol per compound) to identify and quantify the 
levels of NA, DA and 5-HT in the tissue samples. Before analysis of the level of GABA (nmoles/mg wet tissue) 
using o-phthalaldehyde (OPA)–sulphite derivatization and electrochemical detection according to the protocol33, 
the perchlorate extract (0.1 M PCA) was neutralized with NaOH (5.0 M) (~3 μ L in 100 μ L) and diluted 250 × or 
500 × with milliQ water. A Shimadzu autosampler (SIL-10 AF, Shimadzu Corp, Kyoto, Japan) was set to add 2 μ L 
OPA-sulphite solution to 100 μ L diluted sample and after 1 min 5–20 μ L of the derivatized sample was injected 
into the HPLC system. The same type of guard and analytical column as described above for monoamines was 
used. The mobile phase consisted of 0.1 M monosodium phosphate buffer and 0.5 mM EDTA with 25% methanol 
(v/v) water adjusted to pH 4.5 with 1 M phosphoric acid, and the OPA-sulphite solution consisted of 22 mg OPA 
(Sigma-Aldrich Co), dissolved in 0.5 mL sodium sulphite (1 M) to which was added 0.5 mL of absolute ethanol 
and 0.9 mL of sodium tetraborate buffer (0.1 M) adjusted to pH 10.4 with 5 M sodium hydroxide (this solution 
remained stable for 2 days when stored in a dark vial at 4 °C). Flow rate was 0.9 mL/min and the electrochemical 
cell was set to 850 mV vs. Ag/AgCl. An external GABA standard (4–8 pmoles) was injected prior to the tissue 
samples. Under our conditions, GABA eluted at 4.41 min. Data from male and female mice were comparable 
(confirmed by one-way ANOVA with Tukey’s post hoc comparison test (data sets with same variance (Bartlett’s 
test) or Kruskal-Wallis with Dunn’s post hoc comparison test (data with unequal variance (Bartlett’s test)) and 
subsequently pooled. The pooled data, given as pmoles/mg wet tissue (DA, NA, 5-HT) or nmoles/mg wet tissue 
(GABA), were shown as means ± s.e.m., and analyzed using Student’s two-tailed, unpaired t-test with Welch’s post 
hoc correction where indicated in Supplementary Table 6.
Glutamate assay. The mice were decapitated and the brains were quickly removed and dissected. CTX, HC and 
CRBL from 5 mice were pooled and lysates were prepared according to the glutamate assay protocol (Glutamate 
Colorimetric Assay Kit K629-100, BioVision Inc, Milpitas, CA, USA). The protein content in lysates was deter-
mined (Bio-Rad Protein Assay Kit II 500-002, Bio-Rad Laboratories Inc, Hercules, CA, USA), and 4 × 20 μ g 
protein was analyzed for the glutamate content according to the manufacturer’s instructions. The data, given as 
glutamate levels (nmoles/20 μ g protein), were shown as means ± s.e.m. and analyzed using Student’s two-tailed, 
unpaired t-test with Welch’s post hoc correction where indicated in Supplementary Table 5.
Primary mouse cultures. Primary hippocampal mixed astrocyte and neuron cultures of all genotypes were estab-
lished from E17 embryonic mice brains as described previously34. The mixed cultures were seeded at a density of 
0.5 × 105 cells/cm2 and grown in supplemented Neurobasal media (Neurobasal 21203, 1 μ M L-glutamine, B-27 
supplement, 50 μ g/mL penicillin-streptomycin; all reagents were from GIBCO Laboratories). The mixed astro-
cyte neuron cultures were propagated for 20–25 days, to ensure maturation of the astrocytes. Twice a week, 50% 
of the media covering the mixed cultures were replaced. The primary mixed cultures (day 21) were validated by 
immunocytochemistry (data not shown): Culture-covered cover slips were washed 2 × with warm PBS (7.7 mM 
Na2HPO4, 2.3 mM NaH2PO4, 150 mM NaCl), and the cells were subsequently fixed to the cover slip (4% paraform-
aldehyde, for 5 min at 4 °C), and washed 2 × in PBS. The cells were permeabilized (0.1% Triton X-100, for 3 min at 
RT), and washed (1 hour at RT) in PBS with 10% bovine serum albumin (BSA) (Sigma-Aldrich Co). Cover slips 
were incubated with primary antibodies diluted in PBS with 5% BSA (2 hours at RT): Polyclonal goat anti-human 
glial fibrillary acidic protein (GFAP) IgG (C-terminus of GFAP, sc-6170 (C-19), Santa Cruz Biotechnology 
Inc) diluted 1:200, and mouse anti-Pan Neuronal Marker protein IgG (blended monoclonal antibody cocktail, 
MAB2300, Millipore Corp) diluted 1:1 000. After antibody incubation, the coverslips were washed 3 × in PBS 
and incubated with secondary antibodies diluted in PBS with 5% BSA (1 hour at RT): Alexa 488-conjugated 
donkey anti-goat antibody (1:2 000, A11055, Invitrogen Corp, Carlsbad, CA, USA) and Cy3-conjugated donkey 
anti-mouse antibody (1:2 000, 715-165-150, Jackson ImmunoResearch Laboratories Inc, West Grove, PA, USA). 
After 3 × PBS wash, the cover slips were mounted with ProLong Gold antifade reagent with DAPI (P36931, 
Invitrogen Corp) which stains nuclei of both astrocytes and neurons. Fluorescence microscopy examination 
of the stained cover slips revealed that mixed cultures were comparable to the cultures obtained by others34  
(not shown), with a 1:1 ratio of astrocytes and neurons. The specificity of the GFAP antibody was previously con-
firmed on formalin-fixed cerebellar cell primary culture and allowed for staining of astrocyte processes and cell 
bodies (company product sheet), and the specificity of the Pan Neuronal Marker antibody was previously con-
firmed on rat E18 cortex primary cells and allowed for staining of axons, dendrites, nucleus and cell body of neu-
rons (company product sheet). The primary mixed cultures (day 21) were validated by SDS-page Western blotting: 
100 ug of each lysate were separated by SDS-page and Western blotted afterwards essentially as described above. 
The Western blot was divided in two, and the level of α 2-protein (part > 50 kDa) and the control protein, actin 
(part < 50 kDa), was investigated using primary antibodies ((polyclonal rabbit anti-human α 2 aa 432–455, 07674 
Upstate, Millipore Corp) or (monoclonal mouse anti-chicken gizzard muscle actin, 612656, BD Transduction 
Laboratories, Franklin Lakes, NJ, USA)) and incubated over-night at 4 °C in dilution 1: 3 000 in PBS-T with 3% 
BSA. The blot parts were incubated with secondary antibodies ((HRP-conjugated swine anti-rabbit immuno-
globulins, P0399, Dako Inc) or (HRP-conjugated sheep anti-mouse IgG, NXA931, GE Healthcare)) 2 hours at RT 
diluted 1:3 000 in PBS-T with 5% nonfat dry milk. The blots were developed and visualized as described above. 
The intensity of the bands in question was quantified as arbitrary units, AU. Densitometry was performed using 
the ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, http://
imagej.nih.gov/ij/, 1997–2014.), see Supplementary Table 5. The specificity of the actin antibody was confirmed 
on a Western blot of Jurkat cell lysate and allowed for recognition of a protein of 42 kDa (company product sheet).
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[3H]-D-aspartate uptake. On day 21–25, primary mixed cultures (propagated on 18-mm-cover slips in 
12-well-plates) were washed 3 × with 0.5 mL Hepes Krebs-Ringer buffer. Aspartate uptake was allowed for 
5 min at RT by incubation in 0.5 mL PBS containing 200 μ M D-aspartate and [3H]-D-aspartate 0.15 μ Ci/well 
(PerkinElmer Inc, Waltham, MA, USA). Cover slips were rinsed 3 × with 0.5 mL cold Hepes Krebs-Ringer buffer, 
and subsequently lysed in 0.5 mL 0.1 M NaOH. The protein content in all lysates was determined using a method 
adapted from Bradford25 (RC DC protein assay kits, 500-0113 and 500-0114, Bio-Rad Laboratories Inc). The 
content of [3H]-D-aspartate in 0.45 mL lysate was mixed with 5 mL of scintillator (Ready Safe, 141349, Beckman 
Coulter Inc, Brea, CA, USA) and quantified by liquid scintillation spectrometry using a WinSpectral 1414 scin-
tillation counter (Wallac, Turku, Finland). The counts per minute (CPM) were normalized to the protein amount 
(μ g), see Supplementary Table 5. In each experiment, the average [3H]-D-aspartate uptake (CPM/μ g protein) 
for WT samples was set to 100% and, subsequently, all samples were normalized (in %) relative to WT. The nor-
malized data ([3H]-D-aspartate uptake as % of WT) were shown as means ± s.e.m. and analyzed using one-way 
ANOVA, see Supplementary Table 5.
Acoustic startle response. The acoustic startle reflex is a stereotyped motor response evoked by sudden, intense 
acoustic stimuli and characterized by contractions of the major muscles of the body, primarily mediated by a 
relatively simple, oligosynaptic pathway, located in the lower BS, that activates spinal and cranial motor neu-
rons35. The acoustic startle response protocol36 was modified and implemented to the StartFear Combined system 
setup (Panlab Harvard Apparatus) and the accompanying software was used for data acquisition. The mouse was 
placed in a Plexiglas cylinder in the test chamber. The restrained mouse was firstly habituated to the apparatus 
for 5 min and then exposed to 6 series each consisting of 7 sound pulses (none, 80, 90, 100, 105, 110, 120 dB), 
presented in a random order with an inter-trial interval of 30 s. Movements within the cylinder were detected 
and transduced by a piezoelectric accelerometer attached to the Plexiglas base. In all trials, except null trials in 
which there was only background noise (none ~45 dB (mini sound level meter 325, Center Technology Corp, 
New Taipei City, Taiwan)), the pulse was 40 ms. The acoustic startle setup was cleaned and wiped with paper tow-
els between each trial. Data from male and female mice were comparable (confirmed by two-way ANOVA) and 
subsequently pooled. The pooled data, shown as acoustic startle responses (%) at the indicated sound pulses (dB), 
were given as means ± s.e.m., and analyzed using two-way ANOVA and Student’s two-tailed, unpaired t-test, see 
Supplementary Table 4.
Marble burying. Increased marble-burying behavior is well-recognized as a mouse trait that mimics the com-
pulsive behavior of OCD37. The marble burying protocol37 was followed. A mouse was placed in a clear plastic 
box (42 × 26 × 18 cm) containing 25 glass marbles (1.5-cm-diameter) evenly spaced upon a 5 cm deep layer of 
bedding (Tapvei 4HV aspen bedding, Tapvei Ltd, Korteinen, Finland), without food and water. After 30 min, the 
number of marbles buried to at least two-thirds of the depth was counted. The burying was documented by pho-
tography (Canon Digital IXUS 970 IS camera, Canon, Ōita, Japan). The marbles were cleaned with 3 × water and 
wiped with paper towels between each trial, and a clean plastic box with bedding was used per mouse. The data, 
given as marbles buried (n), were shown as means ± s.e.m. and analyzed using Student’s two-tailed, unpaired 
t-test and one-way ANOVA with Tukey’s post hoc comparison test, see Supplementary Table 4. Notably, female 
and male WT mice buried marbles at levels previously observed for a mouse strain with a related background38.
Elevated plus maze. Mice normally display an aversion of open spaces, which involves avoidance of open areas 
by confining movements to enclosed spaces or to the edges of a bounded space, and in elevated plus maze (EPM) 
this translates into preference of movement to the enclosed arms39. The EPM is a plus-shaped maze that is ele-
vated 50 cm above the floor (Stoelting Co, Wood Dale, IL, USA). It consists of two opposite enclosed arms sur-
rounded by 15-cm high opaque walls and two open arms of the same size (5 × 35 cm). The maze was set up 
in a dim lit room under a video camera (Panasonic WV-BP332 Surveillance camera, Panasonic Corp, Tokyo, 
Japan) connected to a computer under the control of the ANY-maze tracking system. Each mouse was placed 
in the center (5 × 5 cm) of the maze facing one of the open arms. Testing sessions of 10 min were carried out for 
each mouse and measured the distance (cm) and the number of entries and the time spent in the open arms. 
The maze was cleaned with 70% ethanol and wiped with paper towels between each trial. The percentage of 
entries into the open arms was calculated as follows: (open arm entries (n)/(open arm entries (n) + closed arm 
entries (n))) × 100, and percentage of time (s) spent in the open arms was calculated as follows: ((total time (s) in 
open arms)/(600 s)) × 100. The experiment was repeated implementing a stress-protocol where the mouse was 
placed 30 min on a 20 × 20 cm transparent platform raised 1 m above the floor prior to the Elevated plus maze 
experiment40. Data from male and female mice were comparable (confirmed by one-way ANOVA with Tukey’s 
post hoc comparison test (data sets with same variance (Bartlett’s test) or Kruskal-Wallis with Dunn’s post hoc 
comparison test (data with unequal variance (Bartlett’s test)) and subsequently pooled. The pooled data, given as 
distance (cm), open arm time (%), open arm entries (%), and line crossings (n), were shown as means ± s.e.m. 
and analyzed using Student’s two-tailed, unpaired t-test with Welch’s post hoc correction where indicated in 
Supplementary Table 4.
Three-chamber social preference. The three-chamber apparatus is a Plexiglas rectangle with two transparent 
partitions that make left, center (center, C), and right chambers (each chamber is 20 × 43 cm) (Stoelting Co). Each 
partition has a square opening (8 × 5 cm) in the bottom center, moreover, the left and right chamber each have 
a 5 cylindrical wire cage (7-cm-diameter) which was used as an inanimate object or the cage housing a stranger 
mouse. The three-chamber unit and wire cups were cleaned with 70% ethanol and wiped with paper towels 
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between each trial. The mouse was placed in the center of the three-chamber unit and after 5 min of habituation, 
the doors were opened. In the next 10-min session, the mouse was allowed access to all three chambers, and in 
one of the chambers an age- and gender-matched C57BL/6 J mouse (stranger, S) that had never been exposed to 
the mouse being tested, was placed in one of the two wire cages. The wire cage on the other side remained empty 
(empty, E). The movement of the mouse was recorded by a Panasonic WV-BP332 Surveillance camera (Panasonic 
Corp) connected to a computer under the control of the ANY-maze tracking system. Time spent in each cham-
ber (chamber time (s)), entries into each chamber (chamber entries (n)), and time spent within a ~2 cm zone 
proximal to each wire cage (sniffing time (s)) were measured. The data, given as chamber time (s), sniffing time 
(s) and chamber entries (n), were shown as means ± s.e.m. and analyzed using one-way ANOVA with Tukey’s 
post hoc analysis, see Supplementary Table 4. Notably, female and male C57BL/6J mice were social, which was in 
agreement with previous findings41.
Tail suspension. Mice with a stress-induced depression-phenotype are immobile for a longer time period com-
pared to controls when tested in the tail suspension test (TST), and they will terminate their escape-like behaviors 
earlier than controls leading to less movement of the body (detected by absolute turn angles). We used the tail 
suspension test (TST)42 to test the α 2+/G301R mice for a stress-induced depression-like phenotype and the tail 
suspension test protocol43 was followed. The mouse was suspended by the tail using adhesive tape to a horizontal 
bar (mouse-tip was raised 60 cm from the ground). The mouse was recorded (Canon Digital IXUS 970 IS camera, 
Canon) for 6 min and mice that climbed their tail were excluded from the experiment (in total four WT mice 
and one α 2+/G301R mouse were omitted due to tail climbing). The majority of the films were examined manually 
(all blindly), and the full immobility time (s) per mouse was determined by use of a stopwatch (data not shown). 
Additionally, all the films were analyzed using the ANY-maze tracking system. Alignment between the manual 
examination and the ANY-maze recordings were ensured and “88% immobility” in the ANY-maze settings gen-
erated an average difference of 6.8% between manual immobility time (s) examination and ANY-maze tracking 
of immobility time (s), n = 33 mice (comparison not shown). Moreover, the ANY-maze tracking system was used 
to examine the absolute turn angles (degrees) per mouse, the number of rotations (n) and the mobility time (s). 
The ANY-maze-generated data were presented in three time intervals on the x-axis adding to 6 min in total. Data 
from male and female mice were comparable (confirmed by one-way ANOVA with Tukey’s post hoc compari-
son test) and subsequently pooled. The pooled data, given as immobility (s), mobility (s), absolute turn angles 
(degrees), and number of rotations (n) in the given time intervals, were shown as means ± s.e.m. and analyzed 
using two-way ANOVA, see Supplementary Table 4. All movies were manually and blindly examined for audible 
squeaks, and if a mouse squeaked it was denoted 100% whereas a silent mouse was denoted 0%. Data from male 
and female mice were comparable (confirmed by one-way ANOVA with Tukey’s post hoc comparison test) and 
subsequently pooled. The pooled data, given as vocalization (%), were shown as means ± s.e.m. and analyzed 
using Student’s two-tailed, unpaired t-test, see Supplementary Table 4.
Stress-induced sucrose preference. The stress-induced sucrose-preference test models the specific depression-like 
syndrome denoted anhedonia44. In the stress-induced sucrose-preference test, normal mice experience pleasure 
from drinking a sweet solution, and reduced preference for a sweet solution over pure water represents an anhe-
donic phenotype (= decreased ability to experience pleasure). The stress-induced sucrose preference protocol44 
was modified. Mice were housed with littermates of same genotype and sex. No previous food or water depriva-
tion was applied before the experiment. Every cage had access to a bottle with pure water and a bottle with 2% 
sucrose solution (1.07687.1000, Merck KGaA, Darmstadt, Germany) which were weighed every day (and the 
exact time point was noted), and the placing of the bottles were swapped to prevent possible effects of side prefer-
ence in drinking behavior. Before the experiment, the mice were habituated to the bottles for 3 days, and hereafter 
consumption was measured by weighing of the bottles. Weighing data in grams (g) were collected for each bottle 
in every cage over a period of 3 days (none), 2 days after completion of the first stress protocol (Stress I) and 2 
days after completion of the second stress protocol (Stress II)). The first stress protocol45 involved 3 × foot shock 
(0.7 mA for 1 s) (Stress I). The second stress protocol involved a series of experiments distributed over a period of 
11 days (Stress II): 2 × tail suspension tests for 6 min (see protocol above), 3 × fixations (inhibitory stress) using 
stress cones (mouse decapicone disposable mouse restrainers DC M200, Braintree Scientific Inc, Braintree, MA, 
USA) for 60 min, and 3 × forced swim tests (the mouse was released into a transparent cylinder (1 L beaker, Ø 
10 cm) filled with 30 °C warm water with a depth of 13 cm for 6 min (the water was regularly changed between 
subjects). For every day, the percentage of sucrose intake was calculated as follows: (sucrose intake (g)/(sucrose 
intake (g) + water intake (g))) × 100, and the liquid intake given as: ((2% sucrose intake (g) + water intake (g)) 
per day/(n) mice in the given cage). For every cage, the average cage-intake of sucrose (%) and liquid consump-
tion (g/mouse/day) over 3 days (None), and 2 days (Stress I and Stress II) were determined. Data from male 
and female mice were comparable (confirmed by one-way ANOVA with Tukey’s post hoc comparison test) and 
subsequently pooled. The pooled data, given as 2% sucrose intake relative to water intake (%) and liquid intake 
(g/mouse/day) at the given protocols, were shown as means ± s.e.m. and analyzed using Student’s two-tailed, 
unpaired t-test with Welch’s post hoc correction where indicated in Supplementary Table 4. Notably, the reduced 
sucrose preference in a subset of WT mice after a stress protocol is in agreement with previous findings46.
Drug administration. Amantadine (A1260-5G, Sigma-Aldrich Co) dissolved in solvent (10 mg/mL, PBS 
(pH 7.4)) was administered by an i.p. injection in a volume of 30 mg/kg 30 min prior to behavioral testing. 
Memantine hydrochloride (M9292, Sigma-Aldrich Co) dissolved in solvent (0.6 mg/ml, PBS (pH 7.4) was admin-
istrated by an i.p. injection of 3 mg/kg 30 min prior to behavioral testing.
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Depoprovera® (50 mg/mL, Vnr 01 70 20, Pfizer ApS, Puurs, Belgium) diluted 2.5 × in PBS (pH 7.4) was 
administered by a subcutaneous (s.c.) injection in the neck in a volume of 100 μ L resulting in 2 mg Depoprovera/
mouse ~3 weeks before (behavioral) experiments.
Bioinformatics. The UCSC genome browser47 was used to examine the human Feb. 2009 (GRCh37/hg19) 
assembly. The microsatellite D1S1677 (UCSC STS id: 5 370) was located to chromosome 1, band q23.3 (163 559 
700-165 360 041) and the full length ATP1A2-gene is located on chromosome 1, band q23.2 (160 085 520-160 113 
374) (uc001fvc.3). The distance from microsatellite marker D1S1677 to the ATP1A2-gene was in the range 3 446 
326-5 274 521 bp’s which corresponds to 3.4-5.3 cM (under the assumption that 1 cM is equivalent, on average, to 
1 million bases in the human genome).
Statistical analysis. All data were shown as mean ± s.e.m. and statistical analyses were done using Prism 
version 5.01 or 6.03 (GraphPad Software Inc, La Jolla, CA, USA or the R software (R Foundation for Statistical 
Computing, Vienna, Austria))48. The obtained male and female mice data were only pooled when this was sta-
tistically validated (P < 0.05), and all statistical tests and the P-values obtained are presented in Supplementary 
Table 4. The Welch’s post hoc correction was used when data sets with unequal variances were analyzed using the 
unpaired two-tailed t-test. The Tukey’s post hoc comparison test was used when data sets with the same variances 
were analyzed using the one-way ANOVA analysis, and the Kruskal-Wallis with Dunn’s post hoc comparison test 
was used when data sets with unequal variances were analyzed using the one-way ANOVA analysis. The threshold 
value (alpha) was set to 0.05.
Results
Generation and basic characterization of the α2+/G301R knock-in (KI) mouse. The G→ A mutation 
in exon 8 encoding the FHM2-associated G301R-mutation was introduced by homologous recombination and 
resulted in α 2+/G301R knock-in (KI) mice (Supplementary Table 1 and Supplementary Fig. 1a). Several analyses 
confirmed successful gene targeting and Cre-recombinase-treatment (Supplementary Fig. 1a–d,f). The distribu-
tion of sex and genotypes among offspring after breeding of C57BL/6 J mice with α 2+/G301R mice (backcrossed to N 
≥ 8) was according to Mendel’s law of segregation (Materials and Methods), and the α 2+/G301R mice appeared nor-
mal and indistinguishable from WT mice by eye. Crossing of two α 2+/G301R mice generated homozygous (− /− ) 
α 2G301R/G301R, heterozygous (+ /− ) α 2+/G301R, and WT (+ /+ ) α 2+/+ pups, which were identified by genotyping 
PCR (Supplementary Fig. 1e). The α 2G301R/G301R pups died immediately after birth resembling the neonatally lethal 
phenotype previously reported for another mouse model targeting the Atp1a2-gene23. The design of all behav-
ioral tests allowed for detection of potential gender-coupled differences, and the obtained male and female mice 
data were only pooled when this was statistically validated (P < 0.05), see Supplementary Table 1. Moreover, all 
behavioral experiments were done blind to genotype with age-matched littermates. Additionally, since ovarian 
hormones can modulate migraine, they may also be able to influence FHM2-related phenotypes, and therefore, 
we conducted our assay, if applicable, to allow discrimination of female and male phenotypes.
Followed for a year, the body weight progression of male α 2+/G301R mice was different from that of WT mice in 
a period of 4 months (interval: 60–190 days), whereas the body weight progression of female α 2+/G301R mice was 
similar to that of WT mice (Supplementary Fig. 1 g), showing that obesity was not a trait of female α 2+/G301R mice.
Western blotting analysis revealed reduced α 2 protein levels in brain lysates from embryonic (E17.5) and 
newborn (day 0) α 2G301R/G301R pups, and they harbored 71% and 94% reduced α 2 protein levels, respectively, 
compared to WT pups (Supplementary Fig. 2a,b). Brain lysates from embryonic and newborn α 2+/G301R pups 
also showed 33–41% reduced α 2 protein levels compared to WT pups (Supplementary Fig. 2a). Moreover, 
hippocampal-derived in vitro cultures established from embryos (E17) of all genotypes harbored 99% reduced 
(α 2G301R/G301R) and 77% reduced (α 2+/G301R) α 2 protein levels compared to WT (Supplementary Fig. 2c and 
Supplementary Table 2). For adult α 2+/G301R mice, reduced α 2 protein levels were found in all male brain areas 
(36–78%) including hippocampus (HC), cerebellum (CRBL), cortex (CTX), and brain stem (BS) compared to WT 
mice (Supplementary Fig. 1b), largely confirmed by parallel analyses of adult female brain lysates (Supplementary 
Fig. 1 h and Supplementary Table 2).
Parallel investigation of the levels of the brain-expressed α -isoforms, α 1, α 2 and α 3, in various brain lysates 
from male and female α 2+/G301R and WT mice showed that comparable levels of α 1 and α 3 isoforms were observed 
in all brain regions (Supplementary Fig. 2d, for quantifications see Supplementary Fig. 2e and Supplementary 
Table 2). Moreover, reduced amounts of the α 2 isoform were observed in all brain lysates from α 2+/G301R mice 
(female and male) compared to WT littermates (Supplementary Fig. 2d, for quantification see Supplementary 
Fig. 2e and Supplementary Table 2).
Recovery phase after cortical spreading depression is prolonged in male α2+/G301R mice. The 
propagation speed of CSD was measured between two recording electrodes during application of potassium ace-
tate (KAc) (Fig. 1a). No differences in the propagation speed of a single CSD event when comparing male α 2v/G301R 
and WT mice were observed (data not shown).
CSD induced a reduction in the ECoG signal in both WT and α 2+/G301R mice (Fig. 1b). After CSD, both the 
depolarization and the disturbances in the brain ion homeostasis regenerate within minutes in the normal brain, 
and in vivo ECoG results showed that regeneration after CSD-induction was significantly reduced in brains from 
male α 2+/G301R mice, compared to WT mice (Fig. 1c,d). Moreover, the evoked potentials had recovered to approx. 
87% of pre-CSD values 15 min after CSD (see Supplementary Table 3), and no difference was observed between 
the genotypes. This is similar to what have been shown in two FHM1 knock-in mouse models49, suggesting that 
the spontaneous activity (ECoG signal) is more likely affected in α 2+/G301R mice than the evoked activity.
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Cerebral blood flow in male α2+/G301R mice is comparable to WT after cortical spreading depres-
sion induction. Human brain scans have shown cerebral blood flow (CBF) changes in migraineurs after CSD, 
denoted spreading oligemia15. Laser-Doppler flowmetry showed that CBF in male α 2+/G301R mice was comparable 
to CBF in WT mice after CSD induction in the timespan (1 hour) investigated (Fig. 1e,f).
Hypoactivity in female α2+/G301R mice is attributed to their sex hormone cycle. Open field and 
rotarod tests revealed that only female α 2+/G301R mice exhibited behaviors different from WT mice (Fig. 2a–d,f), 
where male α 2+/G301R and WT mice were indistinguishable from each other in open field experiments 
(Supplementary Fig. 3). Hypolocomotion was observed in female α 2+/G301R mice as they travelled a shorter dis-
tance and moved more slowly than WT mice (Fig. 2a,b), and female α 2+/G301R mice were also more distressed 
(increased dropping and urination behaviors) compared to WT mice (Fig. 2c,d). Agoraphobia was not a trait 
since the center/perimeter ratios for female α 2+/G301R and WT mice were comparable (Fig. 2e). Endurance, learn-
ing and coordination were decreased in female α 2+/G301R mice, as they spent less time on the accelerated rotarod 
Figure 1. Cortical spreading depression affected the recovery of ECoG signal but not the cerebral 
blood flow. (a) Drawing illustrating the placement of laser-Doppler probe (cerebral blood flow), the glass 
microelectrodes for measuring local field potential (LFP)/ECoG recordings, and the KAc microinjection site 
(for cortical spreading depression (CSD)-induction). (b) Both male α 2+/G301R (n = 7) and WT (n = 6) mice 
showed an overall reduction in electrocorticography (ECoG) signal (mV) following CSD (~1.5 min post CSD). 
(c) ECoG signal (as % of pre CSD) showed that male α 2+/G301R mice (n = 6–7) recover more slowly after cortical 
spreading depression (post CSD) induction compared to WT mice (n = 6–7). (d) Representative examples of 
ECoG signal with DC (traces are shown for the first 15 min, Fig. 1d). (e) Male α 2+/G301R (n = 7) and WT mice 
(n = 7–8) show no difference in the cerebral blood flow (CBF as % of pre CSD baseline) after CSD-induction 
(post CSD). Data shown as means ± s.e.m. ⭑⭑⭑P < 0.001. (f) Representative examples of CBF signal in % of 
pre-CSD baseline are shown for the first 15 min. The CSD is followed by an acute hyperemia followed by an 
extended oligemia (Fig. 1 f). Note that the data was analyzed with 5/10 min interval, thus, the initial hyperemia 
is not seen in Fig. 1 f.
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Figure 2. Hypolocomotion and reduced motor skill learning/coordination of female α2+/G301R mice were 
rescued with Depoprovera. (a,b) Female α 2+/G301R mice (n = 18) travelled a shorter distance (m) (a), and 
moved with a reduced mean velocity (cm/s) (b) compared to WT (n = 13). (c,d) Female α 2+/G301R mice (n = 18) 
produced more droppings (n) (c) and urinations (n) (d) compared to WT mice (n = 13). (e) The center/perimeter 
ratios were the same for female α 2+/G301R (n = 18) and WT mice (n = 13). (f) Female α 2+/G301R mice (n = 5) 
had a decreased latency to fall (s) from the rotarod compared to WT mice (n = 4). (g–j,l) Depoprovera-treated 
female α 2+/G301R (n = 13) and WT (n = 12) mice travelled the same distance (m) (g), moved with the same 
mean velocity (cm/s) (h), had equal dropping (n) (i) and urination (n) (j) behaviors, and female α 2+/G301R mice 
(n = 9) gained comparable latencies to fall (s) from the rotarod to WT mice (n = 8) (l). (k) The center/perimeter 
ratios of Depoprovera-treated female α 2+/G301R (n = 13) and WT mice (n = 12) were the same. Data shown as 
means ± s.e.m. ⭑P < 0.05. (See also Supplementary Figs 3–5).
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compared to WT mice (Fig. 2f). Grip strength was comparable for α 2+/G301R and WT mice (Supplementary Fig. 4) 
reinforcing that α 2+/G301R mice had normal neuromuscular functions.
Depoprovera is a progestin-only contraceptive that suppresses the natural cyclic fluctuations of female sex 
hormones by ensuring a low and stable estradiol level50, and the efficiency of a single subcutaneous injection 
of Depoprovera on the serum estradiol level in WT mice was confirmed (Supplementary Fig. 5). Interestingly, 
Depoprovera-treated female α 2+/G301R mice were indistinguishable from Depoprovera-treated WT mice in all 
open field and rotarod tests, showing that the specific behaviors observed for the untreated female α 2+/G301R mice 
were rescued to WT behaviors (Fig. 2g–j,l).
The α2G301R KI mutation impaired glutamate transport. High performance liquid chromatogra-
phy (HPLC) analyses of lysates (frontal CTX, occipital CTX, striatum (STR), HC, BS, and CRBL) from α 2+/G301R 
and WT mice showed comparable levels of dopamine (DA), noradrenaline (NA), serotonin (5-HT), and 
gamma-aminobutyric acid (GABA) (Supplementary Fig. 6).
Elevated glutamate levels (calorimetrically assayed) were observed in CTX (17%), HC (24%) and CRBL (28%) 
lysates from female α 2+/G301R mice compared to lysates from WT mice (Fig. 3a–c). Furthermore, Depoprovera 
treatment reduced the glutamate levels in CTX, HC and CRBL lysates from female α 2+/G301R mice to levels com-
parable to those from WT mice (Fig. 3a–c). In HC and CRBL lysates from Depoprovera-treated WT mice, the 
glutamate levels were indistinguishable from those from untreated WT mice (Fig. 3b,c). However, in CTX lysates 
from WT mice, the glutamate level was slightly reduced by the Depoprovera treatment (Fig. 3a).
The glutamate transport, measured as [3H]-D-aspartate uptake function, in hippocampus-derived in vitro 
embryo primary cultures derived from α 2+/G301R and α 2G301R/G301R embryos, revealed that glutamate uptake func-
tion was impaired in cultures from α 2G301R/G301R E17 embryonic mice compared to WT (Fig. 3d).
The α2+/G301R mice showed increased responsivity to acoustic stimuli attributed to glutamate 
system defects. Interestingly, both male and female α 2+/G301R mice responded more to the aversive acoustic 
stimuli compared to WT mice (Fig. 4a), and this prompted us to target the glutamate system using a weak antag-
onist (amantadine) of the NMDA type glutamate receptor. Amantadine-administration rescued the increased 
acoustic startle reflex (ASR) behavior in α 2+/G301R mice to that of WT mice (Fig. 4b). In parallel, sham treatment 
with solvent (phosphate-buffered saline (PBS)) had no influence on the ASR behavior in α 2+/G301R and WT mice 
(Fig. 4c), and, moreover, ASR behavior was the same in untreated (none) and amantadine (AMA)- or PBS-treated 
WT mice (Fig. 4d).
Female α2+/G301R mice mimicked more compulsive behaviors than male α2+/G301R mice. For 
mice, pathological grooming behavior is considered to mimic human pathological grooming behaviors as e.g., 
hair pulling (trichotillomania), which frequently co-occurs with obsessive-compulsive spectrum disorders and 
OCD51. Male α 2+/G301R and WT mice displayed comparable levels of grooming behavior whereas female α 2+/G301R 
mice displayed an increased grooming level compared to WT mice (Fig. 4e). Depoprovera treatment reduced the 
grooming behavior of female α 2+/G301R mice to that of female WT mice, but had no effect on the grooming level 
of WT mice (Fig. 4e). The grooming level of female α 2+/G301R mice was comparable to the grooming level in male 
α 2+/G301R and male WT mice, and, the female α 2+/G301R mice had a healthy-looking coat without visible hair-less 
spots. Interestingly, increased facial grooming is described as a specific phenotype in a chronic rat model for 
migraine52, however, our data (Fig. 4e) cover both face and body grooming.
Increased marble-burying behavior of mice mimics compulsive-like behavior of OCD. Interestingly, only 
female α 2+/G301R mice displayed increased marble-burying behavior compared to WT mice (Fig. 4f), and both 
amantadine and memantine treatments rescued their behavior to that of WT mice (Fig. 4g,h). A subgroup (~30%) 
of normally cycling female rats displayed changes in marble-burying behavior along the estrous cycle, burying 
more marble during metestrous compared to proestrous of the menstrual cycle53, showing that marble-burying 
behavior is low in that menstrual phase where the estradiol level is low. Depoprovera treatment rescued the 
increased marble-burying behavior of female α 2+/G301R mice to that of WT mice (Fig. 4i), showing that this behav-
ior was indeed influenced by the female sex hormones.
Bioinformatics assessment does not exclude a genetic basis for OCD coupled to mutations 
in the ATP1A2 gene. The ATP1A2 gene is located on chromosome 1q23.26. A genome-wide linkage scan 
showed a susceptibility locus for an early form of OCD on chromosome 1q with a logarithm of odds (LOD) 
score of + 3 using microsatellite D1S167754. We bioinformatically assessed these data, and found localization 
of microsatellite D1S1677 to the ATP1A2 gene within the genetic distance range of 3.4–5.3 cM. Subsequently, a 
genome-wide association study did not identify any OCD genes55, and future targeted approaches are required to 
elucidate if ATP1A2 is indeed an OCD-linked gene.
α2+/G301R mice are not anxious but display decreased sociability. The α 2+/G301R mice behaved as WT 
mice in the elevated plus maze (EPM) setup (Supplementary Fig. 7a–d). These data are in agreement with the lack 
of agoraphobic behavior in the open field test (Fig. 2e and Supplementary Fig. 3e). Despite implementation of a 
stress-protocol prior to the experiment, stressed α 2+/G301R and WT mice still displayed comparable behaviors in 
the EPM setup (Supplementary Fig. 7e–g).
A three-chamber sociability test showed that WT mice spend more time in the chamber containing the 
stranger mouse (S) than in the chamber containing the non-social/empty wire cage (E) (Fig. 5a). Moreover, WT 
mice spent more time sniffing (in close proximity to) the stranger mouse compared to sniffing the empty wire 
cage (Fig. 5b), and they made more entries into the chamber containing the stranger mouse compared to entries 
into the chamber containing the empty wire cage (Fig. 5c). Contrary to WT mice, the α 2+/G301R mice displayed a 
reduced sociability phenotype and spent comparable amounts of time in both chambers and comparable sniffing 
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Figure 3. Glutamate uptake function and glutamate levels in various female brain areas were affected by G301R 
Mutation(s). (a–c) Glutamate levels (nmoles/20 μ g protein) were determined in lysates from cerebral cortex (CTX) 
(a), hippocampus (HC) (b) and cerebellum (CRBL) (c) of untreated and Depoprovera (DP)-treated female α 2+/G301R 
(n = 2 × 5 and n = 1 × 5, respectively) and WT (n = 2 × 5 and n = 1 × 5, respectively) mice. (d) Glutamate uptake 
function, evaluated as [3H]-D-aspartate uptake (and given as uptake relative to WT uptake (in %)), was reduced in 
hippocampal-derived in vitro-matured mixed cultures of neurons and astrocytes from α 2G301R/G301R (− /− ) (n = 12) 
compared to WT (+ /+ ) (n = 20), but largely similar to WT in culture from α 2+/G301R (+ /− ) (n = 22). Data shown as 
means ± s.e.m. ⭑P < 0.05, ⭑⭑P < 0.01, ⭑⭑⭑P < 0.001. (See also Supplementary Fig. 6).
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Figure 4. Increased acoustic startle response and compulsive behaviors in α2+/G301R mice were rescued 
with amantadine (females and males), memantine or Depoprovera (females). (a,b) Increased acoustic startle 
response (ASR) (%) was observed for α 2+/G301R mice (n = 7–9) compared to WT (n = 7–8) (a) and the ASR was 
rescued by amantadine (AMA) treatment (b). (c,d) Increased ASR (%) was observed for PBS-treated α 2+/G301R 
mice (n = 5) compared to WT (n = 12) (c). ASR (%) of untreated (none) WT mice (n = 8), and WT mice receiving 
amantadine (AMA) treatment (n = 7) or PBS treatment (n = 12) was the same (d). (e) Female α 2+/G301R mice 
(n = 18) groom more than WT mice (n = 12), whereas male α 2+/G301R mice (n = 23) groom as WT (n = 21). The 
increased grooming behavior of female α 2+/G301R mice (n = 13) was rescued by Depoprovera (DP)-treatment, and 
thus comparable to WT mice (n = 12). (f–i) In the marble-burying test, female α 2+/G301R mice (n = 23) buried 
more marbles than WT mice (n = 25) while male α 2+/G301R mice (n = 14) buried marbles as for WT mice (n = 31) 
(f). AMA-treated (g), MEM-treated (h) and DP-treated (i) female α 2+/G301R mice (n = 9, n = 10 and n = 20, 
respectively) and WT mice (n = 11, n = 11 and n = 18, respectively) buried comparable numbers of marbles, 
whereas PBS-injected female α 2+/G301R mice (n = 8–10) buried more marbles than WT mice (n = 11–15) (g,h); the 
difference in marble-burying observed for untreated and PBS-injected female α 2+/G301R mice (f,g,h) is attributed 
the injection 30 min prior to the experiment. The marble-burying data for untreated female α 2+/G301R and WT 
mice were shown both in (f,i). Data shown as means ± s.e.m. ⭑P < 0.05, ⭑⭑P < 0.01, ⭑⭑⭑P < 0.001.
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times to the stranger mouse and the empty wire cage (Fig. 5a,b), and they had the same number of entries into 
both chambers (Fig. 5c).
α2+/G301R mice suffer from stress-induced depression. The tail suspension test (TST), showed that α 2+/G301R 
mice exhibited a stress-induced depression-like phenotype as they displayed increased immobility, reduced 
mobility, reduced movement, and fewer rotations compared to WT mice (Fig. 6a–d). Furthermore, mice become 
vocal in stressful situations56, and during the TST ~50% of α 2+/G301R mice emitted audible squeaks compared to 
~14% of WT mice (Fig. 6e).
The sucrose-preference test models anhedonia44, and unstressed α 2+/G301R and WT mice had a similar and 
high (~98%) preference for sucrose-solution over water (“none”, Fig. 6f). The α 2+/G301R mice displayed anhedonia 
when short- and long-lasting stress protocols were applied prior to the test. Firstly, after a short-lasting stress 
protocol, ~67% of cages housing α 2+/G301R mice reduced their relative sucrose intake compared to 0% of cages 
housing WT mice (stress I, Fig. 6f). Next, a long-lasting stress-protocol resulted in reduced relative sucrose intake 
in ~83% of cages housing α 2+/G301R mice compared to ~20% of cages housing WT mice (stress II, Fig. 6f). The 
relative sucrose intake was rarely below ~90% in any cages, and this can be ascribed to the lack of social stress 
(no individual housing). The overall liquid intake was largely the same in all mice cages during the experiment 
(Fig. 6g).
In summary, the FHM2 mouse model harboring the G301R mutation mimics FHM2-relevant psychiatric 
manifestations, and further associate the α 2Na+/K+-ATPase to both glutamate and female sex hormone systems 
(Table 1).
Figure 5. The α2+/G301R mice displayed reduced sociability. (a–c) In a three-chamber sociability setup, WT 
mice (n = 5) spent more time (s) in the chamber housing a stranger mouse (S) than in the chamber housing 
the empty wire cage (E), whereas α 2+/G301R mice (n = 5) had no preference for either chamber (a). WT mice 
spent more sniffing time (s) around the stranger mouse (S) than the empty wire cage (E), whereas α 2+/G301R 
mice spent the same time (s) sniffing regardless of whether there was a stranger mouse (S) in the wire cage or 
not (E) (b). WT mice had more entries (n) into the chamber housing the stranger mouse (S) than the chamber 
with the empty wire cage (E), whereas α 2+/G301R mice had the same number of entries (n) into both chambers 
(c). C denoted the center chamber separating the two other chambers (E, S). Data shown as means ± s.e.m. 
⭑⭑P < 0.01, ⭑⭑⭑P < 0.001.
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Discussion
FHM is an autosomal dominantly inherited subtype of migraine with aura, characterized by transient neuro-
logical signs and symptoms. FHM2 is a rare disease and, although more severe, it manifests largely as MA and 
fulfils the classic migraine criteria57. A genome-wide linkage scan showed a susceptibility locus for common 
migraine on chromosome 1q, and ATP1A2 (or a flanking gene) was hypothesized to be involved in common 
migraine besides FHM258. Common migraine was recognized as the seventh disabler in the Global Burden 
of Disease Survey 2010 affecting ~14% of adults, and is the most costly neurological disorder59. The episodic 
nature of migraine attacks makes the disease difficult to treat and prevent. Moreover, in the majority of cases, 
migraine is caused by a poorly understood interplay of both genetic and environmental factors, and the frequent 
co-occurrence of a variety of other manifestations further complicates the pathological picture.
Figure 6. The α2+/G301R mice displayed stress-induced depression. (a–e) The α 2+/G301R mice (n = 16) were 
more immobile (s) (a), made fewer turn angles (degrees) (b), made fewer rotations (n) (c) and had reduced 
mobility (s) (d) and a larger fraction of the α 2+/G301R mice emitted audible squeaks (given as vocalization (%)) 
during the experiment (e) compared to WT mice (n = 21). (f,g) Stress-induced sucrose preference test of 
α 2+/G301R mice (n = 15) and WT mice (n = 13) showed that two stress protocols (Stress I and II) had a higher 
influence on the relative sucrose intake (%) of α 2+/G301R mice than that of WT mice. Cages with reduced relative 
sucrose intake (%) compared to unstressed (none) were denoted anhedonic, a, and marked with red filling (f). 
The liquid intake given as liquid/mouse/day (g) was comparable for cages harboring α 2+/G301R and WT mice (g). 
Data shown as means ± s.e.m. ⭑P < 0.05, ⭑⭑P < 0.01, ⭑⭑⭑P < 0.001.
Phenotype/Treatment α2+/G301R
CSD Prolonged recovery phase after CSD induction (males)
Glutamate system
Elevated glutamate levels in adult brain regions (females)
Reduced [3H]-D-aspartate (mixed cultures of neurons and astrocytes 
from α 2G301R/G301R (females and males)
OCD
Increased ASR (females and males)
Increased grooming behaviour (females)
Increased marble-burying behavior (females)
Depression
Stress-induced depression-like phenotype (females and males)
Anhedonia (females and males)
Sociability Reduced sociability (females and males)
Pharmacological treatments
Depoprovera (suppresses the female sex hormone cycle) Rescued 
hypoactivity (females) Rescued grooming (females) Rescued marble 
burying behavior (females)
Amantadine (glutamate antagonist) Rescued ASR (females and males) 
Rescued marble burying behavior (females)
Memantine (glutamate antagonist) Rescued marble burying behavior 
(females)
Table 1.  Summary of major phenotypes and pharmacological treatments.
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To reach a better understanding of the pathological spectrum of migraine, knowledge of the molecular 
pathway(s) involved and the co-morbid manifestations are warranted. To address these issues, we generated a 
knock-in mouse model introducing the FHM2-causing G→ A mutation in the Atp1a2 gene encoding the FHM2 
mutation, α 2G301R. The analyses of α 2-protein expression all suggest that FHM2 is caused by α 2 haploinsuffi-
ciency, with WT protein levels of the brain-expressed paralogs α 1 and α 3 isoforms in brain stem (BS), hippocam-
pus (HS), cerebellum (CRBL) and cortex (CTX). These results are comparable to the expression of α 1 and α 3 
isoforms in total brain lysates reported for the α 2 W887R knock-in mouse model19.
Our results showed that the α 2+/G301R mouse displayed several behavioral phenotypes, which have relevance 
for FHM2/MA, co-morbid mood depression and OCD. Moreover, these manifestations occurred in patients 
from two FHM2-families harboring the α 2G301R mutation4,20. Both male and female α 2+/G301R mice showed 
specific behavioral phenotypes most likely coupled to imbalance in the glutamate system and probably involving 
the NMDA receptor, and a mechanism(s) behind FHM2 may be the result of reduced glutamate clearance by 
astrocytes involving the α 2Na+/K+-ATPase11,12. We provide evidence that both genetic (the Atp1a2 G301R muta-
tion) and physiological (female sex hormone) factors modulate co-morbid psychiatric manifestations relevant to 
FHM2. Both clinical and epidemiological data on hormonal modulation of FHM2-related manifestations are lim-
ited, but other lines of evidence towards hormonal influence of FHM-related phenotypes exist, and are described 
below in relation to observed phenotypes for the α 2+/G301R mice.
The initiation of CSD is largely dependent on high levels of extracellular glutamate and K+ ions15. The K+ ions 
are released after neuronal activity, and believed to accumulate due to decreased removal of K+ and glutamate by 
astrocytes. This leads to a wide-arching depolarization which compromise further neuronal firing. The NMDA 
receptor is a prime “target” for excessive extracellular glutamate, and this receptor does play an important role in 
the initiation, propagation and duration of CSD60. Although the male α 2+/G301R mice showed CSD propagation 
speed and cerebral blood flow measurements comparable to male WT mice, this is not conclusive as several fac-
tors effect the variation of the propaganda speed (e.g, a CSD wave can spread in several directions from the point 
of induction and not necessarily move in a straight linear direction, which means that the time it takes for the 
CSD to spread from the site of elicitation can differ between the two electrodes. Moreover, the alignment of the 
two electrodes may be affected by e.g presence of blood vessels). However, the electrocorticography revealed that 
the recovery phase after CSD was affected.
In comparison, the α 2+/W887R KI mouse model displayed a decreased threshold for CSD induction and an 
increased CSD velocity of propagation19. The differences between these studies, and the studies presented here, 
likely reflects the different assay conditions i.e., KAc was used for CSD induction in the right somatosensory 
cortex in the male α 2+/G301R mice, whereas incremental current stimuli were delivered up to CSD induction in 
the occipital cortex in the α 2+/W887R KI mice. Moreover, the different use of anesthetics (α -chloralose versus ure-
thane) could also explain the differences observed. Notably, previous studies of other anesthetics were shown to 
influence the CSD induction threshold and propagation speed differently61.
Moreover, in line with a previous study of two FHM1 knock-in mouse models49, the level of recovery of 
evoked potentials 15 min. after CSD is the same in WT and α 2+/G301R mice, indicating that the spontaneous activ-
ity (ECoG signal) is affected whereas the evoked activity is not. The fact that the evoked potentials do not fully 
recover to pre-CSD levels, as observed for the two FHM1 knock-in mouse models49, probably reflects that some of 
the mechanisms that underlie this unfiltered EEG signal have not recovered within the time frame of the experi-
ment. Further study of two different FHM1 knock-in mouse models showed that the female knock-in mice were 
more susceptible to CSD49 than male knock-in mice, and this sex difference was abolished by ovariectomy and 
senescence, proving a role for the female sex hormone cycle—besides the genetics—in the susceptibility to CSD. 
In this context, it is interesting that the α 2+/G301R mice displayed additional female-specific behaviors related to 
both the glutamate system and the female sex hormone cycle, indicating that female α 2+/G301R mice might be more 
sensitive to the (molecular) alterations that the α 2G301R-mutation cause, and thus, the penetrance of specific 
behavioral phenotypes might therefore be higher compared to male α 2+/G301R mice.
There is a preponderance of females among migraineurs suffering from FHM, sporadic hemiplegic migraine 
(SHM) and familial non-hemiplegic MA5,62. The levels of total estrogen and estradiol were elevated in migraineurs 
with aura at the two stages (menses and ovulation) investigated compared to control group63. Notably, MA has 
been considered an absolute contraindication to the use of combined hormonal contraception64, and preliminary 
results showed that progestin-only contraception had a positive effect in the course of MA, reducing the number 
of days with migraine65. Several of the female-specific behaviors of α 2+/G301R mice were rescued to WT behav-
iors by a single Depoprovera treatment that reduced/stabilized the estrogen levels. A previous study has shown 
that treatment of fertile rats with a raloxifene-analog reproduced the effects observed after ovariectomy, proving 
that the raloxifene-analog functioned as an anti-estrogen in the cerebral brain areas investigated66. Moreover, 
in vitro studies of raloxifene-treated astrocytes demonstrated an increase in glutamate uptake14, showing that an 
anti-estrogen effect mediated by the estrogen receptor enhances glutamate clearance of astrocytes.
There is increasing evidence that alterations in glutamatergic neurotransmission contributes to migraine67. 
EAAT2 is predominantly expressed in astrocytes and is crucial for glutamate uptake in the central nervous sys-
tem68. Moreover, previous in vitro studies indicated a role for the α 2Na+/K+-ATPase, in complex with EAAT1 
and EAAT2, in astroglial glutamate uptake, i.e., glutamate clearance from the synaptic cleft11,12. We showed that 
glutamate uptake is impaired in vitro in hippocampal-derived matured mixed cultures of astrocytes and neurons 
obtained from α 2G301R/G301R E17 embryonic mice compared to WT. In mixed cultures, neurons will support gluta-
mate uptake, but to a much lower degree than the astrocytes69. Although embryonic and adult neurons do express 
the α 3 isoform (which has a lower sodium affinity than the α 2 isoform), and thus, could support sodium-coupled 
glutamate uptake, it is unlikely that the difference in glutamate uptake observed between the mixed cultures 
derived from α 2G301R/G301R homozygous and WT E17 embryonic mice, represents a difference in neuronal gluta-
mate uptake.
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The α 2 isoform is expressed in a differential developmental manner: the α 2 isoform is mainly found in astro-
cytes and in a small subset of hippocampal neurons in the adult brain7, which is in contrast to the newborn 
brain, where the α 2 isoform is predominantly found in neurons70. This indicates that the reduced glutamate 
uptake in the matured mixed astrocyte and neurons cultures from the α 2G301R/G301R mice (mimicking adult con-
ditions) should mostly be attributed to the lack of a functional α 2Na+/K+-ATPase in astrocytes, however, lack 
of a functional α 2Na+/K+-ATPase in the subset of neurons, which would normally express a functional α 2Na+/
K+-ATPase, could also account for a fraction of the reduced glutamate uptake observed.
Moreover, we observed higher levels of glutamate in lysates from various brain areas from adult female α 2+/G301R 
mice compared to lysates from WT mice, although, it remains to be elucidated whether the increased glutamate 
level is derived from extra- and/or intracellular compartments. Altogether, these data support that the molec-
ular mechanism behind FHM2 is coupled to the glutamate system and coupled to reduced glutamate clear-
ance of astrocytes involving the α 2Na+/K+-ATPase. Estradiol has previously been shown in vitro to enhance 
depolarization-induced presynaptic glutamate release71 and in vivo to increase both the total glutamate level and 
the extracellular glutamate level in the arcuate nucleus72. Our results are in agreement with the hypothesis that 
estrogen plays a significant role in the auto-regulation of brain (and blood) glutamate levels73. Furthermore, our 
results suggest that high levels (and/or fluctuating levels) of estradiol might aggravate the effects on the glutamate 
system caused by haploinsufficiency of the gene encoding the α 2-isoform of the Na+/K+-ATPase.
Studies of migraineurs with aura (between attacks) and migraine-prone children showed that they exhibited 
an increased responsiveness to aversive acoustic stimuli74,75. Increased ASR behavior is also observed in patients 
with OCD76, and, to date, adult females from two different FHM2-families—one harboring the α 2G301R muta-
tion—have been diagnosed with OCD besides FHM24,77. Moreover, accumulating evidence (neuroimaging, ani-
mal models, candidate gene and treatment studies) points to the fact that glutamate system defects might lead to 
OCD78,79, which is in agreement with cerebrospinal fluid from OCD-affected adults containing increased gluta-
mate levels compared to controls80. Notably, different psychiatric manifestations (including OCD) are reported 
to be co-morbid to MA81.
A human study based on questionnaires to female outpatients with primary OCD showed that reproduc-
tive cycle events do influence the symptom severity of OCD82. The female-specific α 2+/G301R mice behaviors 
mimicking compulsive behaviours of OCD could be rescued to WT behaviors by Depoprovera and memantine 
(an NMDA receptor antagonist83), whereas OCD-related female- and male-specific α 2+/G301R mice behavior could 
be rescued to WT behavior by treatment with amantadine (an NMDA receptor antagonist84). Our results showed 
that behaviors likely resulting from lack of proper glutamate clearance of astrocytes could be circumvented by 
treatment with amantadine or memantine, which both are proposed to allow normal synaptic transmission but 
decreasing over-activation of NMDA-receptors84,85. Selective serotonin reuptake inhibitors (SSRIs) are currently 
the first-line OCD-treatment, however, ~40–60% of OCD-patients remain refractory to treatment with SSRIs86.
The association between anxiety and migraine has been observed in both clinic- and community-based stud-
ies87. Moreover, an epidemiological study reported the presence of anxiety disorders in 75.8% of the OCD patients 
studied88. Notably, mild anxiety was reported in an FHM2-family during attacks89, however, the α 2+/G301R mice 
did not appear anxious in the EPM assay. This is different compared to previous FHM2 mouse models, which 
showed an increased susceptibility to fear and anxiety19,23,90 and most likely, this could be either attributed to 
different mouse inbred strains, or the fact that different exons and mutations were knocked-out or introduced, 
respectively, mimicking the complex genotype-phenotype in FHM2 patients. To date, social phobia has not been 
reported for any FHM2 family. However, a population study showed association between migraine and social 
phobia91. Moreover, an epidemiological study reported a 43.5% prevalence of social phobia/anxiety in OCD 
making this anxiety disorder the most frequently observed anxiety disorder co-morbid to OCD88. The α 2+/G301R 
mice showed behavior characteristic for decreased sociability, supporting clinical findings for migraine and OCD 
patients.
Population studies demonstrated that depression was co-morbid with migraine92, and mood depression was 
described for a FHM2-family harboring the α 2G301R-mutation4. Moreover, an epidemiological study reported 
that 63.3% of OCD-patients suffered from a mood disorder besides OCD88. In line with these studies, the α 2+/G301R 
mice exhibited stress-induced depression. Altogether, our data support the opinions that co-morbid psychiatric 
manifestations to migraine/FHM2 should be considered part of the pathological spectrum.
The behavioral phenotypes of α 2+/G301R mice are likely caused by an intricate interplay of effects that are gen-
erated by reduced glutamate clearance from the synaptic cleft, and they seem to be aggravated and extended in 
female α 2+/G301R mice by effects of the female sex hormone cycle hereon. The alterations in the glutamate system 
in male and female α 2+/G301R mice and the role of the female sex hormone cycle in female-specific α 2+/G301R mice 
behaviors, open up a range of possibilities for developing optimal strategies to successfully treat FHM2/migraine 
patients with co-morbid psychiatric manifestations.
Some clinical limitations apply to our study. Firstly, the experiments were performed in mice, which are 
imperfect models of human neurological disorders. Secondly, a few studies exist describing the therapeutic effects 
of different NMDA receptor antagonists on migraine or migraine related symptoms93,94, however, it is uncertain if 
FHM2 patients would benefit from treatment with amantadine, memantine or other NMDA receptor antagonists. 
Interestingly, a recent study showed that amantadine could improve obsessive compulsive symptoms when used 
as an adjunctive therapy to selective serotonin reuptake inhibitors (SSRIs) in OCD-patients refractory to SSRI 
pharmacotherapy alone95. These results support the hypothesis that dysfunctional transduction of the glutamate 
signal via the NMDA receptor play a role in OCD, and thus, may play a similar role in OCD co-morbid to FHM2. 
Thirdly, the female sex hormone cycle might prove valuable as a target for treatment of females suffering from 
FHM2 and/or common migraine, however, this will require further clinical testing.
www.nature.com/scientificreports/
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